Roche Signs a License Agreement with Shape to Advance AAV-based RNA Editing Technology for Neuroscience and Rare Disease

Shots:

Shape is eligible to receive $3B+ including initial payment, development, regulatory, and sales milestone along with royalties on sales of therapies resulting from the collaboration
The collaboration will utilize Shape’s RNA editing platform i.e., RNAfix and AAVid for next-generation tissue-specific AAVs to develop gene therapy for AD, PD & rare diseases
Shape to conduct preclinical research to identify & deliver development candidates discovered by RNAfix and AAVid AI-powered platforms. Roche will lead the development & global commercialization of any potential products that emerge from the collaboration

Click he r e to read full press release/ article | Ref: Globe Newswire | Image: PharmaLive